Paperonium

Immunology · Sci Adv · 2021

The summary says the drug “reduces” white-cell self-destruction. The paper’s own tests show it rises.

Its main textsays the same, five timesLab dish, 10 hoursabout 85% vs 45% with dummyInflamed mice, days 1–2larger share of white cells deadsame as without the drugThe summary“reduces” self-destruction
Its main textsays the same, five timesLab dish, 10 hoursabout 85% vs 45% with dummyInflamed mice, days 1–2larger share of white cells deadsame as without the drugThe summary“reduces” self-destruction

Which way the drug moves the self-destruction of white cells

The paper says

White blood cells called neutrophils gather in inflamed tissue, then self-destruct; the paper says this helps the inflammation die down. Yet the summary at the top of the paper says its antibody drug, meant to end inflammation, “reduces” this self-destruction.

Its own data show

In a lab dish, after 10 hours, about 85% of drug-treated cells showed signs of self-destructing, versus about 45% with a do-nothing dummy. In inflamed mice, at 1 and 2 days, a larger share of white cells at the inflamed spot were dead with the drug. The paper’s main text says the same, five times.

Cells dying sounds bad, but here it is good: the paper calls appropriate self-destruction of these cells “fundamental” to ending inflammation, and ties delayed self-destruction to inflammatory bowel disease. Anyone reading only the summary gets this effect backwards. The data and main conclusions are not affected: in mice, inflammation still cleared faster with the drug.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution · Sci Adv (2021) · doi:10.1126/sciadv.abd1453